Cardiff Oncology Inc’s filing revealed that its Chief Financial Officer Levine James E. acquired Company’s shares for reported $14905.0 on Dec 17 ’24. In the deal valued at $5.42 per share,2,752 shares were bought. As a result of this transaction, Levine James E. now holds 65,316 shares worth roughly $0.23 million.
Then, Levine James E. bought 2,400 shares, generating $12,000 in total proceeds. Upon buying the shares at $5.00, the Chief Financial Officer now owns 67,716 shares.
Before that, Levine James E. bought 2,564 shares. Cardiff Oncology Inc shares valued at $9,820 were divested by the Chief Financial Officer at a price of $3.83 per share. As a result of the transaction, Levine James E. now holds 62,564 shares, worth roughly $0.22 million.
Craig Hallum initiated its Cardiff Oncology Inc [CRDF] rating to a Buy in a research note published on September 06, 2024; the price target was $8. A number of analysts have revised their coverage, including William Blair’s analysts, who began to cover the stock in early January with a ‘”an Outperform”‘ rating. Robert W. Baird began covering CRDF with “an Outperform” recommendation on December 08, 2021.
Price Performance Review of CRDF
On Monday, Cardiff Oncology Inc [NASDAQ:CRDF] saw its stock fall -3.88% to $3.47. Over the last five days, the stock has lost -26.17%. Cardiff Oncology Inc shares have fallen nearly -20.05% since the year began. Nevertheless, the stocks have risen 97.16% over the past one year. While a 52-week high of $6.42 was reached on 01/06/25, a 52-week low of $1.44 was recorded on 01/13/25. SMA at 50 days reached $3.43, while 200 days put it at $3.14.
Levels Of Support And Resistance For CRDF Stock
The 24-hour chart illustrates a support level at 3.37, which if violated will result in even more drops to 3.28. On the upside, there is a resistance level at 3.60. A further resistance level may holdings at 3.74. The Relative Strength Index (RSI) on the 14-day chart is 44.41, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.49, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 95.95%. Stochastics %K at 5.13% indicates the stock is a buying.
How much short interest is there in Cardiff Oncology Inc?
A steep rise in short interest was recorded in Cardiff Oncology Inc stocks on 2024-12-13, growing by 2.23 million shares to a total of 9.95 million shares. Yahoo Finance data shows the prior-month short interest on 2024-11-15 was 7.72 million shares. There was a rise of 22.44%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on October 22, 2020 when H.C. Wainwright began covering the stock and recommended ‘”a Buy”‘ rating along with a $27 price target.
